Articles tagged with: Revlimid

News»

[ by | Feb 18, 2015 7:43 pm | 2 Comments ]
FDA Broadens Revlimid's Approved Use To Include Newly Diagnosed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has ex­panded the of­ficial­ly ap­proved use of Revlimid to include the treat­ment of newly diag­nosed multiple myeloma.

Previously, Revlimid’s approval in the U.S. and elsewhere in the world was for the treat­ment of myeloma patients who have re­ceived at least one prior therapy.

With the expanded U.S. approval, there no longer is any re­striction regard­ing prior therapies in the FDA-approved pre­scrib­ing in­for­ma­tion for Rev­limid (lena­lido­mide).

The new edition of the pre­scrib­ing in­for­ma­tion says simply that “Revlimid in combination with dexa­metha­sone is …

Read the full story »

News, Opinion»

[ by | Jan 30, 2015 3:07 pm | 4 Comments ]
The Myeloma Quiz – January 2015

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the Inter­na­tional Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it …

Read the full story »

News»

[ by | Dec 10, 2014 3:12 pm | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions throughout the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immunotherapeutic approach to treating cancer …

Read the full story »

News»

[ by | Oct 14, 2014 8:59 am | 15 Comments ]
British Researchers Document Potential Solution For Revlimid Gastrointestinal Side Effect

The results of a small British study may lead to fewer myeloma patients suf­fer­ing from diarrhea while taking Revlimid.

In a short article published last week, researchers from the Royal Marsden Hospital in London report that a condition known as “bile acid mal­ab­sorp­tion” appears to be a frequent cause of the diarrhea experi­enced by some patients during treatment with Revlimid (lena­lido­mide).

The researchers also found that the bile acid mal­ab­sorp­tion and re­sult­ing diarrhea in these patients can be addressed in two ways.

For some patients, reducing consumption of …

Read the full story »

News»

[ by | Aug 4, 2014 6:51 pm | 16 Comments ]
Kyprolis Succeeds In Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Planned For Europe And Other Countries

Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial com­par­ing Kyprolis-Revlimid-dex­a­meth­a­sone to Revlimid-dex­a­meth­a­sone in pa­tients with relapsed multiple myeloma.

Patients in the trial who received the Kyprolis-Revlimid-dex­a­meth­a­sone com­bi­na­tion (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dex­a­meth­a­sone (Rd) (17.6 months).

There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. How­ever, the difference is not yet statistically significant.

The results of the trial are important for two …

Read the full story »